Bio-Techne Corporation (NasdaqGS:TECH) is rolling out a new brand architecture centered on three portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. The updated structure ...
Bio-Techne Corporation, a global provider of life science research tools, analytical instruments, and diagnostics, today ...
Christine Willett is a Senior Manager of Quality in the Diagnostics division at Bio-Techne, overseeing quality operations at ...
StockStory.org on MSN
1 S&P 500 stock to own for decades and 2 we question
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors ...
A number of stocks jumped in the afternoon session after the reopening of the Strait of Hormuz signaled a cooling of global logistics and energy costs.
Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...
Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing Enables up to 24 targets per sample and supports ...
The DCF model implemented in this article suggests that Bio-Techne is overvalued by 34.53%. Bio-Techne has allocated significant financial resources to capex. Due to these resources, its revenues ...
Bio-Techne TECH reported fourth-quarter fiscal 2025 adjusted earnings per share (EPS) of 53 cents, which surpassed the Zacks Consensus Estimate by 6%. The bottom line improved from the year-ago figure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results